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xinanwu6511@163Abstract The aim of this study was to investigate the pharmacokinetics of glibenclamide (Gli)
administrated orally and intravenously to normal and diabetic rats. The AUC(0–720 min) of orally
administered Gli in diabetic rats (321.24 mg min/L) was greater than that (57.752 mg min/L) in
normal rats. CL (0.019 L/min/kg) was signiﬁcantly slower than that (0.092 L/min/kg) of normal
rats. The AUC(0–480min) of intravenous Gli in diabetic rats (1528.280 mg min/L) also was
signiﬁcantly greater than that (509.523 mg min/L) in normal rats, and CL was decreased
approximately 3-fold. No signiﬁcant difference in intestinal absorption of Gli was observed
between normal and diabetic rats as determined by in situ single-pass intestinal perfusion. The
clearance of Diclofenac (a substrate of CYP2C9) was determined to evaluate changes in hepatic
drug-metabolizing enzyme activity in rats. The CL in diabetic rats was signiﬁcantly lower (42.43%
decrease) than that in normal rats. Hepatic protein expression of CYP2C9 was measured using
Western blot analysis; compared with normal rats, the hepatic protein expression of CYP2A9 was
decreased in diabetic rats. Therefore, the slower clearance of Gli in diabetic rats can be attributed
primarily to the lower expression of hepatic CYP2C9.
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Changes in the pharmacokinetics of glibenclamide in rats with streptozotocin-induced diabetes mellitus 1991. Introduction
Diabetes mellitus is a complex endocrine metabolic disorder.
Clinically, the main consequence of hyperglycemia is second-
ary impairments in various tissues and organs. Some compli-
cations such as cardiovascular disease, kidney disease,
retinopathy, and nervous system diseases result in substantial
morbidity and mortality1. What is especially noteworthy is
that the pharmacokinetic parameters of many drugs are
altered in diabetes2–5. The possible reasons for these pharma-
cokinetics changes are diverse and complex, including gastro-
intestinal lesions which cause changes in drug absorption6;
changes in transporters responsible for uptake, efﬂux and
elimination7; changes in liver drug enzymes which alters
metabolic rate8; nephropathy which leads to changes of drug
transport, metabolism and elimination9. However, the phar-
macokinetic parameters of drugs are usually determined from
healthy subjects. In clinical studies it has been reported that
drug accumulated in some diabetic patients10, and diabetes
may inﬂuence pharmacodynamics and increase the adverse
effect of hypoglycemic agents. Therefore, the study of drug
pharmacokinetics in the diabetic state is important and
beneﬁcial for clinical development.
Glibenclamide (Gli), as an oral medicine, is available to
treat type 2 diabetes mellitus. The pharmacokinetics of Gli in
healthy subjects11 and patients with type-2 diabetes12,13 has
been studied. However, a comparison of the pharmacokinetics
of Gli between diabetes patients and healthy volunteers has
not been reported. Thus, the pharmacokinetic differences of
Gli in normal and streptozotocin (STZ)-induced diabetic rats
after oral and intravenous administration were investigated
and compared in this study. The mechanism of pharmacoki-
netics changes was clariﬁed based on intestinal absorption and
hepatic drug-metabolizing enzyme studies. The pharmacoki-
netics of Gli in rats was investigated with HPLC, and the
intestinal absorption of Gli was investigated by single-pass
intestinal perfusion studies in situ. Gli is metabolized to several
hydroxylated derivatives, 4-trans-hydroxy-glibenclamide (M1)
and 3-cis-hydroxy-glibenclamide (M2), by cytochromes P450
2C9 (CYP2C9) in the liver14,15; thus, diclofenac (a substrate of
CYP2C916) was chosen as a probe to measure the activity of
CYP2C9 and the hepatic protein expression of CYP2C9 was
investigated using Western blot analysis.2. Materials and methods
2.1. Chemicals and reagents
Gli and diclofenac were purchased from the Chinese Medicine
Control Institute (Beijing, China). STZ was purchased from
Sigma Chemicals (USA). A glucose oxidase test kit was
purchased from Merit Choice Bioengineering Co., Ltd (Beijing,
China). Acetonitrile was HPLC grade, obtained from Shandong
Yuwang Co., Ltd (Jinan, China). RIPA lysis buffer (Beyotime,
China), rabbit anti-CYP 2C9 (Boisynthesis, China), peroxidase-
conjugated afﬁnipure goat anti-rabbit secondary antibodies
(Boster, China), mouse anti-b-actin (Boster, China) and goat
anti-mouse secondary antibodies (Boster, China) were used in
Western blot analysis. Distilled water was freshly prepared by the
ﬁrst hospital of Lanzhou University. Other solvents were of
analytical grade.2.2. Animals
Male Wistar rats weighing 210–250 g were purchased from the
Laboratory Animal Center of Lanzhou University (Lanzhou,
China). All rats were maintained on a standard diet with free
access to water in standard and conditioned animal houses at
the ﬁrst hospital of Lanzhou University for one week. The rats
were fasted for 18 h with free access to water overnight before
the experiment. Animal experimental protocols were reviewed
and approved by the Institutional Animal Experimentation
Committee of Lanzhou University.
2.3. Induction of diabetes induced by STZ
Diabetic rats were induced by single intraperitoneal injection
of STZ, 60 mg/kg in citrate buffer (pH 4.5)17. During the
pretreatment rats had free access to food and water. 5 days
later blood was collected from tail snips into polypropylene
tubes containing heparin to measure glucose using a glucose
oxidase test kit. All rats which had a plasma glucose level
exceeding 16.5 mM were accepted as being diabetic rats.
2.4. Plasma sample preparation
The plasma (0.1 mL) was vortex-mixed with 0.2 mL of
acetonitrile containing diazepam (0.205 mg/mL) as internal
standard (IS) for 30 s to deproteinate, and then centrifuged
at 10,000 rpm for 5 min. The supernate was transferred into
1.5 mL tubes containing 40–50 mg sodium chloride. The
suspension was vortex-mixed and allowed to separate for
10 min. The upper acetonitrile layer was transferred to another
centrifuge tube and dried under nitrogen in 40 1C water bath.
50 mL of acetonitrile was added to the residue, resuspended by
ultrasonication, vortexed for 30 s and then centrifuged at
10,000 rpm for 5 min. A 20 mL aliquot was injected into the
HPLC system.
2.5. Pharmacokinetics of glibenclamide after oral
administration
The procedures for pretreatment of rats were reported pre-
viously18. A polyethylene tube was inserted into the right
femoral artery of the normal or diabetic rats while the animals
were under anesthesia. After the animals regained conscious-
ness a Gli solution was orally administered to normal rats
(n¼5) and diabetic rats (n¼5) at a dose of 10 mg/kg. Blood
samples (0.25 mL) were collected into heparinized tubes at 0
and 15, 30, 60, 75, 90, 120, 150, 180, 240, 360, 540 and 720 min
from the femoral artery. After each sampling, loss of blood
volume was supplemented with an equal volume of saline
containing 100 U/mL heparin. Plasma (0.1 mL) was with-
drawn and centrifuged at 10,000 rpm for 5 min and then kept
frozen at 20 1C until analyzed.
2.6. Pharmacokinetics of glibenclamide after intravenous
administration
Gli solution was intravenously administered to normal rats
(n¼5) and diabetic rats (n¼5) at a dose of 5 mg/kg via the
femoral vein. Blood samples (0.25 mL) for Gli analysis were
collected at 0 and 3, 6, 10, 15, 20, 40, 60, 90, 120, 180, 300 and
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plasma sample preparation processes were the same as those
in the oral administration study.
2.7. Absorption of glibenclamide studies in rats
2.7.1. Intestinal absorption model
Gli solution (0.6 mg/mL, dissolved in Kreb’s solution19) were
perfused into the duodenum, jejunum and ileum of normal
(n¼5) and diabetic rats (n¼5). The measurement of intestinal
absorption was carried out by in situ single-pass intestinal
perfusion (SPIP) as described in previously published
reports20. Brieﬂy, rats were anesthetized and put on an electric
blanket maintained at 37 1C. The abdomen was opened with a
midline incision. Various intestinal segments were separated
and inserted with PVC tubing of appropriate diameter.
Normal saline solution was used to keep the exposed segments
moist at 37 1C. The tubes were connected to a peristaltic pump
to form local circulatory system. Intestinal segments were ﬁrst
washed with Kreb’s solution at a rate of 2.0 mL/min until
outlet solution was visually clear. Thereafter, the segments
were perfused at a ﬂow rate of 0.2 mL/min with test solution
cycled for 15 min. The inlet tubing ﬁlled with warmed
perfusion solution (37 1C) was weighed. Each perfusion
experiment lasted for 120 min and samples were collected at
a time interval of 15 min into preweighed glass tubes. All the
perfusate collected was weighed. Finally, at the end of the
experiment the length of each intestine segment was measured.
The radius of the intestine was taken to be 0.2 cm21. All
samples including perfusion samples at different time points,
original drug solution, and inlet solution taken at the exit of
the syringe were centrifuged at 10,000 rpm for 10 min, and
20 mL of the supernatant was injected into the HPLC system.
2.7.2. Data processing
In this paper, the weight of solutions22,23 was used to eliminate
the impact of volume changes of the inﬂow and outﬂow
perfusate volume. The absorption rate constant (Ka) and the
apparent absorption coefﬁcient (Papp) were calculated by the
following equation:
Ka ¼ ð1CoutVout=CinVinÞQ=V ð1Þ
Papp ¼ ½Qin  lnðCoutVout=CinVinÞ=2prl ð2Þ
where Vin and Vout were the inlet and outlet volume of
perfusate solution (mL), respectively, the density of perfusate
solution is assumed to be 1.0 g/mL; Cin and Cout were inlet
and outlet concentration of perfusate solution (mg/mL); Q was
ﬂow rate perfusion (mL/min); l and r were the length and
diameter of intestines (cm); V was the volume of perfused
segments (cm3).
2.8. Pharmacokinetics of diclofenac after intravenous
administration
Diclofenac solution at a dose of 10 mg/kg was injected via the
femoral vein to normal rats (n¼5) and diabetic rats (n¼5).
Blood samples (0.25 mL) were collected via the femoral artery
at 0 and 3, 6, 10, 15, 20, 40, 60, 90, 120, 180, 300 and 480 min
after the beginning of the infusion. Other procedures were the
same as those used in the oral administration of Gli study.Plasma (0.1 mL) for determination of diclofenac concentration
was vortex-mixed with 0.2 mL of acetonitrile containing Gli
(84.4 mg/mL) as internal standard for 30 s to deproteinate, and
20 mL of supernate was injected into the HPLC system.
2.9. HPLC analysis
The HPLC analysis was carried out using a Shimadzu LC-20A
HPLC system (Kyoto, Japan) which consisted of a binary
gradient pump (model LC-20A), a SPD-20MA diode-array
detector, a SiL-20A auto sampler, a DGU-20A3 degasser and
CTO-20A column oven. The apparatus was interfaced to a
DELL PC compatible computer using LC solution software.
Concentrations of Gli or diclofenac in the above samples were
analyzed by HPLC method developed in our laboratories.
The separation was performed on a Waters SunFireTM C18
column (150 mm 4.6 mm, 5 mm). The ﬂow rate was kept
constant at 1.0 mL/min and the temperature of oven was
maintained at 40 1C. The mobile phase used in Gli separation
was methanol –0.2% acetic acid in water (63.5: 36.5, v/v). The
mobile phase used in diclofenac detection is methanol–0.1%
acetic acid in water (70:30, v/v). The mobile phase was freshly
prepared daily and ﬁltered through 0.45 mm membrane ﬁlter.
Gli and diclofenac were detected at 229 nm and 275 nm,
respectively. The injection volume for all the samples was
20 mL. All concentrations were calculated from the standard
curve of Gli and diclofenac obtained from spiked plasma
samples. The methods were validated in terms of speciﬁcity,
linearity and reproducibility. The result showed linearity of
Gli and diclofenac over the concentration range of 0.0156–1.5,
1.5–15 mg/mL (r2¼0.9994) and 0.469–30 mg/mL (r2¼0.9996),
respectively. The limit of quantiﬁcation (S/NZ3) of Gli and
diclofenac in plasma was 3 mg/L and 8 mg/L. The limit of
quantiﬁcation (S/NZ10) of Gli and diclofenac in plasma was
8 mg/L and 20 mg/L. The intra- and inter-day variations of Gli
and diclofenac were less than 3%.
2.10. Western blot and CYP2C9 analysis
Rats livers from normal rats and STZ-induced diabetic rats
(n¼3, each group) were immediately excised after the rats were
sacriﬁced and total protein was isolated by RIPA lysis buffer.
The supernatant fraction was obtained through centrifugation at
10,000 g for 10 min at 4 1C and then stored frozen at 80 1C.
Protein content was measured using the Micro BCA protein
assay, using bovine serum albumin as standard protein. 100 mg
protein was analyzed by a 10% SDS-polyacrylamide gel electro-
phoresis and then transferred to a PVDF transfer membrane.
Following the transfer, the membrane was blocked with 5% non-
fat dried milk dissolved in the phosphate-buffered saline contain-
ing 0.05% tween 20 (TBST) for 1.5 h. The PVDF membrane was
incubated with a 1/200 diluted rabbit anti-CYP 2C9 antibody
in TBST containing 5% non-fat dried milk with shaking at room
temperature for 2 h. After three washes with TBST, it was
further incubated with peroxidase conjugated afﬁnipure goat
anti-rabbit IgG secondary antibodies, goat anti-rabbit IgG
(diluted 1/5000 with TBST containing 5% non-fat dried milk)
with shaking for 1.5 h and then washed three times with TBST.
Hepatic CYP2C9 were detected by enhanced chemiluminescence
on ﬁlm and quantiﬁed by densitometry with a microcomputer
imaging device. The b-actin band was used as a loading control.
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The software of DAS 2.0 was used to estimate the pharma-
cokinetic parameters. Statistical analyses were performed
using unpaired t-test. Numerical values in tables and ﬁgures
were expressed as means7standard deviation (SD). Means
were assumed to be statistically signiﬁcant when Po0.05.3. Results
3.1. Pharmacokinetics of glibenclamide after oral
administration to rats
The normal and diabetic rats were given Gli 10 mg/kg by oral
administration. The average plasma concentration-time pro-
ﬁles of Gli are illustrated in Fig. 1. The plasma concentrations
of Gli in diabetic rats were higher than those in normal rats.
The pharmacokinetic parameters, calculated by the software
of DAS 2.0, in the normal group and in diabetic group were
compared with a t-test and results are shown in Table 1.
It shows that the peak plasma drug concentration (Cmax) isFigure 1 Average plasma concentrations of Gli after oral admin-
istration (10 mg/kg) to normal rats (n¼5) and diabetic rats (n¼5).
Values are expressed as Means7SD.
Table 1 Pharmacokinetics parameters of Gli after oral
administration at the dose of 10 mg/kg to normal rats and
diabetic rats.
Parameter Normal rats Diabetic rats
Tmax (min) 84.784715.961 255.427723.795
n
Cmax (mg/mL) 0.25970.031 0.91070.142
n
CL (L/min/kg) 0.09270.012 0.01970.008n
AUC(0–720 min)
(mg min/L)
57.752718.932 321.247130.374n
Data are expressed as Mean7SD, n¼5. Cmax, peak plasma
concentration; Tmax, time to reach Cmax; CL, total body
clearance; AUC(0–720 min), area under the plasma concentra-
tion–time curve from time 0 to 720 min.
nPo0.05.0.259 mg/mL in normal rats, and 0.910 mg/mL in diabetic rats,
respectively. Cmax in diabetic rats was signiﬁcantly higher
(3.51-fold) than that in normal rats (Po0.05); the time to
reach Cmax (Tmax) was increased from 84.784 min in normal
rats to 255.427 min in diabetic rats. The area under the plasma
concentration-time curve (AUC(0–720 min)) in diabetic rats
increased 5.56-fold (321.24 mg min/L in diabetic rats versus
57.752 mg min/L in normal rats) (Po0.05). The total body
clearance (CL) was 0.092 L/min/kg in normal rats, however,
CL was 0.019 L/min/kg in diabetic rats (Po0.05). The CL in
diabetic rats was 4.84 times lower than that in normal rats.
3.2. Pharmacokinetics of glibenclamide after intravenous
administration to rats
The average plasma concentration–time curves of Gli
after intravenous administration at the dose of 5 mg/kg
to normal and diabetic rats are shown in Fig. 2. Plasma
concentrations of Gli in diabetic rats were also markedly higher
than those of normal rats, as shown. The pharmacokinetic
parameters are summarized in Table 2. After intravenous
administration in diabetic rats, the AUC(0–720 min) in diabetic
rats (1528.280 mg min/L) was also signiﬁcantly greater than that
in normal rats (509.523 mg min/L) (Po0.05), and this was not
due to increased absorption in the diabetic rats. The systematic
CL in diabetic rats (2.667 L/min/kg) was decreased approxi-
mately 3-fold relative to that in normal rats (7.612 L/min/kg)
(Po0.05). The half-life (T1/2) of Gli in normal and diabetic
rats was determined to be 225.466 min and 560.902 min,Figure 2 Average plasma concentrations of Gli after intravenous
administration (5 mg/kg) to normal rats (n¼5) and diabetic rats
(n¼5). Values are expressed as Means7SD.
Table 2 Pharmacokinetics parameters of Gli after injec-
tion administration at the dose of 5 mg/kg to normal rats
and diabetic rats.
Parameter Normal rats Diabetic rats
T1/2 (min) 225.466725.337 560.9027166.224
n
CL ( 103, L/min/kg) 7.61271.528 2.66770.701n
AUC(0-480 min)
(mg min/L)
509.523756.136 1528.2807214.489n
Data are expressed as Mean7SD, n¼5.
nPo0.05.
Table 3 Absorption parameters of Gli between normal rats and diabetic rats studied with SPIP.
Intestinal
segment
Ka ( 102, min1)
normal rats
Ka ( 102, min1)
diabetic rats
Papp ( 103, cm/min)
normal rats
Papp ( 103, cm/min)
diabetic rats
Duodenum 1.17470.172 1.61670.206 1.18170. 233 1.74870.559
Jejunum 1.96370.109 2.25370.173 1.51070.325 2.24670.103
Ileum 0.89770.151 0.77670.097 0.91570.147 0.75270.079
Data are expressed as Mean7SD, n¼5. Ka: absorption rate constant; Papp: the apparent absorption coefﬁcient.
Figure 3 Average plasma concentrations of diclofenac after
intravenous administration (10 mg/kg) to normal rats (n¼5) and
diabetic rats (n¼5), data are expressed as Mean7SD.
Table 4 Pharmacokinetics variables of diclofenac after
injection at the dose of 10 mg/kg to normal rats and
diabetic rats.
Parameter Normal rats Diabetic rats
T1/2 (min) 170.076724.725 288.930746.333
n
CL ( 103, L/min/kg) 11.28771.082 4.66770.577n
AUC(0-480 min)
(mg min/L)
684.604763.473 1468.445745.059n
Data are expressed as Mean7SD, n¼5.
nPo0.05.
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335.436 min.
3.3. Intestinal absorption results
In situ SPIP in normal and diabetic rats was carried out as
followed: 0.6 mg/mL Gli solution was perfused to the proximal
and distal segments as single perfused segments. The absorption
rate constant (Ka) and the apparent absorption coefﬁcient (Papp)
obtained by the study of in situ perfusion to the duodenum,
jejunum and ileum from the normal and the diabetes rats are
presented in Table 3. Ka of duodenum, jejunum and ileum in
normal rats was found to be 1.174 102, 1.963 102 and
0.897 102/min, respectively. Ka of Gli in duodenum, jejunum
and ileum in diabetic rats was 1.616 102, 2.253 102 and
0.776 102/min, respectively. There was no signiﬁcant difference
between normal and diabetic rats. Papp of Gli in normal rats was
1.181 103 cm/min in duodenum, 1.510 103 cm/min in jeju-
num and 0.915 103 cm/min in ileum. The Papp of Gli in
diabetic rats was 1.748 103 cm/min in duodenum, 2.246 103
cm/min in jejunum and 0.752 103 cm/min in ileum. The data
indicates that Gli was mainly absorbed in the jejunum and
duodenum both in normal and diabetic rats and permeability of
Gli in each intestine between normal and diabetic rats was not
signiﬁcantly different.
3.4. Pharmacokinetics of diclofenac after intravenous
administration to rats
In this study hepatic drug-metabolizing enzyme activity was
estimated by measuring the systemic clearance and AUC ofdiclofenac, a probe drug for CYP2C9. Following the intrave-
nous administration of diclofenac at 10 mg/kg to normal and
diabetic rats the average plasma concentrations of diclofenac
were higher in the diabetic rats than those in the normal
rats (Fig. 3). Signiﬁcant pharmacokinetics differences were
found between the two groups (Table 4). T1/2 in diabetic rats
(288.930 min) was longer than that in normal rats (170.076 min).
The CL in diabetic rats (11.287 L/min/kg) was lower than that in
normal rats (4.667 L/min/kg).3.5. Protein expression of hepatic CYP2C9
The hepatic protein expression of CYP2C9 is shown in Fig. 4.
In diabetic rats the protein expression of CYP2C9 was 56.42%
of that of normal rats (Po0.05).4. Discussion
Gli is a second generation sulfonylurea drug used for the
treatment of type 2 diabetes24. It signiﬁcantly stimulates islet b
cells to release insulin, and its hypoglycemic effect is obvious. It is
easy to produce hypoglycemia after oral therapy25. Pharmacoki-
netic parameters of Gli are usually determined from healthy
volunteers; however, complications from diabetes may result in
pharmacokinetics changes in these patients. Thus it is important to
study pharmacokinetics in the state of diabetes. According to the
current data, it was evident that the pharmacokinetics of Gli after
oral and intravenous administration was signiﬁcantly different
between normal and diabetic rats. The basis for these changes in
Gli pharmacokinetics was determined by measuring intestinal
absorption and the activity of liver drug metabolizing enzymes.
It was reported that Gli was a substrate of P-glycoprotein
(P-gp)26 which was responsible for efﬂux of drugs. According
to reports in the literature, the expression of P-gp was low in
intestine in diabetes27,28. Therefore, the intestinal absorption
of Gli might be increased in diabetic rats, which could be the
Figure 4 The result of Western blot analysis. (A) Representative
Western blot of hepatic CYP2C9 in normal rats (n¼3) and
diabetic rats (n¼3), b-actin band was used as a loading control;
(B) Protein expression of hepatic CYP2C9. The results of normal
rats were deﬁned as 100%. nPo0.05 is considered signiﬁcant.
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oral administration. Gli is a weak acid, thus Gli is easily
absorbed under acidic conditions, such as duodenum and
jejunum. The expression of P-gp increased from proximal to
distal29, with lower expression P-gp in duodenum and jeju-
num. Thus the change of P-gp expression was probably not a
major factor in the absorption difference between normal and
diabetic rats. Brockmeier et al.30 indicated that the stomach
was also one of the main absorption sites of Gli. Autonomic
nervous system control of gastrointestinal tract resulted in
delayed gastric emptying in diabetic patients and rats31–33. The
longer residence time of Gli in the stomach may result in
greater absorbance of Gli in the stomach in diabetic rats. This
could result in the increased AUC in diabetic rats.
Gli is eliminated equally by bile and kidney34,35. The diabetes
induced by STZ could bring about kidney damage36, although the
clearance of Gli does not relate to an abnormality of the kidney37.
According to these results, it was presumed that signiﬁcantly lower
elimination of Gli in diabetic rats was caused by change in the
liver and not kidney damage. Gli is metabolized by CYP2C9 in
the liver. Abnormal glucose homeostasis in diabetes mellitus can
result in liver disease, known as diabetic hepatopathy38,39. What’s
more, there are many reports of changes in hepatic drug
metabolizing enzymes in diabetes and other diseases8,40–42. Giving
diclofenac (a substrate of CYP2C9) intravenously to diabetic rats
yielded a signiﬁcantly lower CL than that in normal rats. Changes
in diclofenac pharmacokinetic parameters in diabetic rats sug-
gested that metabolic differences between normal and diabetic rats
might be due to the change in CYP2C9 expression in rats with
diabetes. The Western blot data demonstrated that the protein
expression of CYP2C9 was decreased signiﬁcantly compared with
normal rats.
In conclusion, the pharmacokinetics of Gli after oral and
intravenous administration between normal and diabetic ratsdiffered. Compared with normal rats, the expression of
CYP2C9 in hepatic microsomes decreased in diabetic rats
and was one of the main mechanisms for the lower clearance.
The results of the present study may be of signiﬁcance for
clinical practice.
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